XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$26.11 USD
-0.81 (-3.01%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $26.05 -0.06 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
XOMA 26.11 -0.81(-3.01%)
Will XOMA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
Other News for XOMA
Zevra?s MIPLYFFA? (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty to Present at Upcoming Investor Conferences in September
Risinger Affirms Buy Rating on Xoma with Increased Price Target Amid Strong Financial Performance and Unrecognized Asset Potential
Buy Rating Affirmed: Xoma’s Strategic Growth and Financial Strength Highlighted